STUDY QUESTION: What is the prevalence and source of prospectively and retrospectively registered and unregistered trials in fertility treatments?
Introduction
Systematic reviews aim to summarise the results from more than one study in order to provide an unbiased assessment of medical and health interventions. The inclusion of biased research studies in systematic reviews, such as those with errors in methodology or study design, can result in misleading conclusions (Moher et al., 1998) . Therefore, assessing the quality of the individual clinical trials is an important step in conducting a systematic review (Higgins and Green, 2011) . Systematic reviews also aim to find and include all available studies and by doing so reduce the chance of publication bias (Higgins and Green, 2011) . Publication bias occurs when only easy to find studies are included, these tend to be the published, larger studies with positive results, while the smaller studies with negative effects may not be published and are more difficult to find (Dickersin and Min, 1993) . By including all studies, publication bias is reduced (Simes, 1986; Hopewell et al., 2009) . Trial registration was introduced in an effort to reduce publication bias. In 2004, the International Committee of Medical Journal Editors (ICMJE) recommended that all clinical trials should be registered and stated 'All ICJME member journals will require, as a condition of consideration for publication, registration in a public trials registry ' (DeAngelis et al., 2004) . Prior to that time registering a clinical trial was voluntary. Even with the introduction of the registries rates of trial registration have remained low (McGee et al., 2011; Wager and Williams, 2013; Riehm et al., 2015; Scott et al., 2015) . Trial registration information can be found in various regional and international trial registries such as clinicaltrials.gov, operated by the US National Institutes of Health and the collated trial registry portal provided by The World Health Organisation, The International Clinical Trials Registry Portal (ICTRP) (Evans et al., 2004; Zarin et al., 2005) .
There has been a call for unregistered trials to be excluded from systematic review. Roberts et al. (2015) suggested that unregistered trials are likely to have lower methodological quality than prospectively registered trials and therefore should not be included in systematic reviews. We have already reported that the risk of bias is higher in randomised controlled trials (RCTs) that are not prospectively registered (Farquhar et al., 2017) . The aim of the current study was to report on prospective and retrospective trial registration in RCTs of fertility treatments.
Methods

Data sources and searches
The data reported here were collected as part of a project assessing the risk of bias in registered and unregistered trials (Farquhar et al., 2017) . We searched the Cochrane Gynaecology and Fertility Group's specialised register (PROCITE) for RCTs of fertility treatments using the search strategy described by Farquhar et al. (2017) .
Study selection
All full text RCTs published in English language from first January 2010 to 31 December 2014 were included.
Data extraction
For all eligible clinical trials, registration status and the timing of registration was sought firstly from the paper, then in the clinical trial registries, these included clinicaltrials.gov and the ICTRP portal. If the information was not available we then contacted the authors for further details. We also recorded the sample size, year of publication, journal of publication and the first author's country of affiliation. A full description of the methodology is published (Farquhar et al., 2017) .
Prospective registration was defined as a trial registered prior to the commencement of patient enrolment in accordance with ICMJE requirements (DeAngelis et al., 2004) . In addition, we reported trials that were registered after the trial start date but within 6 months of participant enrolment. Six months was chosen as an arbitrary figure as it was anticipated that this would allow for inclusion of trials that had been retrospectively registered after enrolment but prior to analysis of trial results. Retrospective registration was defined as any study that was registered 6 months or more after the start of participant recruitment.
Data analysis
Results are presented descriptively and graphically using Microsoft Excel.
Results
From 2010 to 2014 there were 943 eligible trials for fertility treatments on the Cochrane Gynaecology and Fertility group register (Fig. 1) . Two hundred fifty were excluded because they were written in a language other than English (123 trials), were out of scope (115 trials), or were duplicated by other publications (12 trials). Of the 693 RCTs that met the inclusion criteria, 309 (45%) were confirmed as registered. Of the 309 registered trials only 22% were prospectively registered and 38% were registered within 6 months of the initiation of participant enrolment. Annual trial registration rates did not change substantially over the 5 year period, ranging from 40% in 2010 to 48% in 2014, with a peak registration rate of 53% in 2011 and prospective trial registration was 5% of all trials in 2010 and 8% of all trials in 2014 with 8% and 30%, respectively, for those registered within 6 months of the start of trial recruitment (Fig. 2) .
The 693 RCTs were published from 42 countries, as classified by first author affiliation. Finland, New Zealand, Dubai and Vietnam were the only countries with 100% of their trials registered. Iran was the most prolific, publishing 109 trials of which 70 were registered with Egypt having the second highest publication rate, with 77 trials of which only 31 were registered. These top two countries accounted for 27% of all publications in this area Table I . The top 10 countries were responsible for 76% (n = 526) of publications in the area of fertility of which 45% were registered. Of the 10 countries most frequently publishing trials, Belgium and the Netherlands had the highest proportion of registered trials with 89% and 77%, respectively, and Turkey and India were the lowest with 16% and 13%, respectively (Fig. 3 ). For the top 10 countries, most frequently publishing trials Egypt (87%) and Iran (80%) had the highest proportion of retrospective trial registration.
One hundred and sixty journals published 693 clinical trials from 2010 to 2014. Fertility and Sterility published the highest number of trials (n = 125) with Human Reproduction the next highest publisher (n = 54) (Supplementary Table SI) . We have reported the proportion of prospectively registered trials for the three most frequent journals in Fig. 4 . Over the 5 years Human Reproduction had the highest proportion of prospectively registered trials (26%), followed by Fertility and Sterility (15%) and Reproductive Biomedicine Online (8%). There has been a reduction in the proportion of retrospectively registered trials from 2010 and 2014 in all three journals. Table II provides details of the trial registration policy for these three journals. A list of the journals publishing trials and the percentage registered is shown in Supplementary Table SI. Forty six percent of trials were researching IVF or ICSI (n = 318) with research related to PCOS the next most frequent with 17% of trials (n = 115). In Fig. 5 we report the timing of the trial registration by area of research. The area of research with the highest number of publications is IVF/ICSI and the prospective registration rate was 12% (not including tubal disease as only four trials).
Discussion
This study has reported on trial registration, both prospective and retrospective, for fertility treatments. Although the ICMJE's call for compulsory trial registration dates back to 2004, between 2010 and 2014 only 45% of fertility trials were registered, and the annual trial registration rates did not improve substantially over this time. Moreover, of the registered trials only 22% were prospectively registered. While trial registration is essential for publication in some journals (Hooft et al., 2014) , we have shown that many journals are continuing to publish unregistered clinical trials, and that researchers' compliance with trial registration differs between countries. This finding agrees with other studies showing lower than expected trial registration rates (Reveiz et al., 2012) This finding is important as we have also shown that prospectively registered trials are of higher methodological quality than retrospectively or unregistered trials where we observed that registered trials differed from unregistered trials in their risk of bias, across the domains of random sequence generation, allocation concealment, and selective reporting. (Farquhar et al., 2017) . In addition, unregistered clinical trials were generally smaller, with nearly half of unregistered trials based on less than 100 participants. These findings need to be balanced against the need to avoid publication bias which would be increased if retrospectively registered trials were excluded. Although the risk of bias is greater with unregistered trials it is our view that their data should still be available in the public domain, in data repositories such as the clinical trials registry hosted by the United States National Institutes of Health (www.clinicaltrials.gov). This would mean that the data could be included in systematic reviews after assessing risk of bias. All of these results lead to the conclusion that prospective registration of clinical trials is important but in general is uncommon. It seems unlikely that this is unique to fertility trials, as studies from surgery, psychiatry, medicine and others have reported similar findings although they have not always made the distinction of prospective and retrospective registration (Mathieu et al., 2009; Huic et al., 2011; Scott et al., 2015; Killeen et al., 2014) . Late registration to meet journal requirements for publication as an afterthought is not best practice. Despite the ICJME's recommendations, our data indicates that prospective trial registration is not routine, at least in the reproductive medicine field, and a significant proportion of published trials are unregistered. Human Reproduction has announced that it will require this prospective trial registration from January 2017 which is a welcome move (Evers, 2017) .
Considering the low compliance with trial registration regardless of timing, excluding unregistered trials from systematic reviews may greatly reduce the number of trials available for analysis, reducing the statistical power of the meta-analysis, and potentially introducing publication bias into the review. Moreover, as trial registration prevalence differs widely 
Conclusions
We have reported that prospective trial registration remains unacceptably low in fertility trials. This is important as the risk of bias is lower in trials with prospective trial registration. Although there are encouraging steps being made it is our view that editors of journals, ethics committees and funders of trials could do more to ensure trial registration is prospective.
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